Pharmacogenetics of ophthalmic topical β-blockers [PDF]
, 2008 Glaucoma is the second leading cause of blindness worldwide. The primary glaucoma risk factor is elevated intraocular pressure. Topical β-blockers are affordable and widely used to lower intraocular pressure.
McCarty, Catherine A. +4 more
core +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Risperidone is a commonly used antipsychotic for treating psychiatric illness in children and adolescents. There is a large variability in risperidone response and discontinuation rates remain high. Pharmacogenomics offers the opportunity to improve risperidone outcomes, yet studies in pediatric populations are limited.
Jack W. Staples +10 more
wiley +1 more source
Pharmacogenomics landscape of COVID-19 therapy response in Serbian population and comparison with worldwide populations [PDF]
Journal of Medical Biochemistry, 2020 Background: Since there are no certified therapeutics to treat COVID-19 patients, drug repurposing became important. With lack of time to test individual pharmacogenomics markers, population pharmacogenomics could be helpful in predicting a higher risk ...
Stanković Biljana +7 more
doaj
Pharmacogenetics of analgesic drugs [PDF]
, 2013 • Individual variability in pain perception and differences in the efficacy of analgesic drugs are complex phenomena and are partly genetically predetermined.
Branford, R +4 more
core +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.5‐hydroxytryptamine type 3 (5‐HT3) receptor antagonists are used to treat nausea and vomiting and in the prevention of chemotherapy‐induced, radiation‐induced, and postoperative nausea and vomiting. Most of the 5‐HT3 receptor antagonists (i.e., ondansetron, tropisetron, dolasetron, palonosetron, and ramosetron) are metabolized by CYP2D6, but the extent
Claire Moore +16 more
wiley +1 more source
An Update to the Clinical Pharmacogenetics Implementation Consortium (CPIC) SLCO1B1 Allele Functionality Table Leveraging Evidence from Participants of Predominantly Sub-Saharan African Ancestry. [PDF]
Clin Pharmacol TherThe Clinical Pharmacogenetics Implementation Consortium (CPIC) has formally updated the SLCO1B1 allele functionality table based on new evidence. Notably, the alleles studied (SLCO1B1 *9, *31, *41) are enriched in the genomes of patients historically excluded from pharmacogenomics research.
Oni-Orisan A +6 more
europepmc +2 more sources
Mismatch repair SNPs and thyroid cancer susceptibility: a potential role for the MSH6 rs1042821 (Gly39Glu) polymorphism [PDF]
, 2015 of the Poster presented at the 3rd ESPT Conference (European Society of Pharmacogenomics and Personalised Therapy / European Society of Pharmacogenomics and Theranostics), 7-9 October 2015 ...
Azevedo, A. P. +8 more
core
The integration and interpretation of pharmacogenomics. A comparative study between the United States of America and Europe: towards better health care [PDF]
, 2016 The study of pharmacogenomics has, by harnessing sequence information from human genomes, the potential to lead to novel approaches in drug discovery, an individualized application of drug therapy, and new insights into disease prevention.
Bartlett, MJ, Shephard, EA
core +1 more source
Pharmacogenomic testing and its future in community pharmacy [PDF]
, 2020 Although it is common to see pharmacogenomic testing used North America and Australia, it is not yet part of practice in the UK. With the promise of genomic screening becoming part of the NHS, pharmacists must equip themselves with a knowledge of how the
Wright, David, Youssef, Essra
core +1 more source
A Computational Workflow for Cell Line Profiling by Imaging Mass Cytometry
Cytometry Part A, EarlyView.ABSTRACT In single‐cell spatial phenotyping biology, imaging mass cytometry (IMC) stands out as a cutting‐edge, highly multiplexed technology driving discoveries across various disease areas. In vitro profiling relies on tumor‐derived cancer cell lines, known for their diverse morphologies and phenotypes.
Alexandre Bouzekri +2 more
wiley +1 more source